<DOC>
	<DOCNO>NCT01034475</DOCNO>
	<brief_summary>Chemotherapy resistance major cause death patient advance hematologic malignancy . The propose novel mechanism action , non-cross resistance chemotherapeutic agent currently use clinic , lack CPI-613-related myelosuppression preclinically clinically date make CPI-613 suitable candidate phase I clinical trial patient . The current trial one several clinical trial CPI-613 . Other clinical trial conduct patient solid tumor already initiate . The primary objective study determine safety MTD CPI-613 administer 2x weekly 3 consecutive week . The secondary objective determine PKs CPI-613 follow IV administration observe anti-tumor effect CPI-613 , occur .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Maximum Tolerated Dose ( MTD ) , Efficacy , Pharmacokinetics ( PKs ) CPI-613 Given Twice Weekly Three Consecutive Weeks Patients With Advanced Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>histologically cytologically document relapsed and/or refractory hematologic malignancy Karnofsky Performance Status ( KPS ) &gt; 70 % . Must â‰¥18 year age . Expected survival &gt; 1 month . Women childbearing potential must use accepted contraceptive method No radiotherapy , treatment cytotoxic agent ( except CPI613 ) , treatment biologic agent anticancer therapy within 3 week prior treatment CPI613 . Serious medical illness , significant cardiac disease ( e.g . symptomatic congestive heart failure , unstable angina pectoris , myocardial infarction within past 6 month , uncontrolled cardiac arrhythmia , New York Heart Association Class III IV ) , severe debilitate pulmonary disease , would potentially increase patient ' risk toxicity . Patients active central nervous system ( CNS ) epidural tumor . Any active uncontrolled bleeding , patient bleed diathesis ( e.g. , active peptic ulcer disease ) . Pregnant woman , woman childbearing potential use reliable mean contraception . Lactating female potential excretion CPI613 breast milk . Life expectancy le 1 month . Any condition abnormality may , opinion investigator , compromise safety patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>acute lymphoblastic leukemia</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>chronic myeloid\ leukemia blast phase</keyword>
</DOC>